Viyash Scientific Limited (formerly SeQuent Scientific Limited), which operates across formulations, APIs and CDMO services for human and animal health, has reported its strongest-ever quarterly performance for the period ended March 31, 2026.
The company reported revenues of ₹9,200 million for Q4 FY26, up 19.1 per cent compared to the corresponding quarter last year, while EBITDA excluding ESOP costs rose 63.9 per cent to ₹2,001 million.
Profit after tax for the quarter stood at ₹664 million against a loss of ₹322 million in the year-ago period.
For the full financial year FY26, the company posted revenues of ₹34,203 million, registering a growth of 13.8 per cent year-on-year. EBITDA for the year rose 59.6 per cent to ₹7,025 million, while PAT surged 1324 per cent to ₹2,246 million.
The company said its net debt-to-EBITDA ratio stood at 0.2x, reflecting a significantly deleveraged balance sheet and improved financial discipline.
Commenting on the performance, Dr Hari Babu Bodepudi, Managing Director and Group CEO, said FY26 was a transformative year for the company, marked by the integration of facilities, operations and corporate functions into a unified platform.
“Q4 was the strongest quarter in the Company’s history, with merger synergies beginning to reflect meaningfully in our financial performance. The integrated platform has strengthened execution, improved operating leverage, and enhanced our resilience amidst ongoing geopolitical and maritime disruptions,” he said.
He added that the company continues to address external challenges through disciplined asset utilisation, cost controls and agile pricing strategies, while also evaluating selective inorganic opportunities supported by its deleveraged balance sheet.
Viyash Scientific Limited is an integrated pharmaceutical enterprise with operations across India, Spain, Brazil, Turkey and the USA, serving customers in more than 100 countries.
